Unfolded protein response (UPR) is a cellular adaptive response that functions to reduce stress caused by malfolded proteins in the endoplasmic reticulum (ER). UPR can be induced under physiological or pathological conditions and is responsible for the pathogenesis of many human diseases. Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus causing chronic diseases. Its genome encodes two envelope proteins E1 and E2, which mature in the ER to form a noncovalently bound, native complex and disulfide aggregates and have previously been shown to induce expression of the molecular chaperone immunoglobulin heavy chain binding protein. In this study, we show that HCV envelope protein expression regulates another stress indicator CCAAT/enhancer-binding protein-homologous protein (CHOP). The ER-stress element and the activating transcription factor 4 element in the CHOP promoter were activated to a similar extent by HCV envelope protein expression. Using mouse embryonic fibroblasts deficient in the ER stress kinase RNA-activated protein kinase-like ER-resident kinase (PERK), we showed that PERK was necessary and sufficient for activating the CHOP promoter. Expression of HCV E1 and/or E2 also induced splicing of X-box binding protein 1 and transactivation of the unfolded protein response element, leading to the speculation that HCV E1 and E2 not only regulate the UPR but also ER-associated degradation.
transcription factor 6 (ATF6α/β), IRE1α/β, and RNA-activated protein kinase (PKR)-like ERresident kinase (PERK), all of which are under the negative regulation of BiP (6, 7) . In nonstressed cells, these UPR sensors are bound by BiP in an inactive state. Signaling through these UPR sensors requires de-repression of the inhibitory effect of BiP by the accumulation of malfolded proteins, which dissociate BiP from the UPR sensors, allowing them to migrate into the Golgi or dimerize for their activation (6, 7) . Upon release from BiP, ATF6 migrates to the Golgi, where it is cleaved sequentially by site-1 protease and site-2 protease to release an active transcription factor into the nucleus to transactivate UPR genes harboring an ER-stress element (ERSE) in their promoters (7) . IRE1 and PERK are activated by dimerization and autophosphorylation (6) . IRE1 is a kinase/endoRNase (8) . The endoRNase activity of IRE1 mediates unconventional splicing of X-box binding protein 1 (XBP1) for its productive translation into an active transcription factor to transactivate UPR genes with an ERSE and also ERAD genes with a mammalian UPR element [UPRE; (9, 10) ]. Transactivation of the mammalian UPRE provides a link between the UPR and the ERAD, as UPRE-mediated transcriptional induction of ER degradation-enhancing α-mannosidase-like protein (EDEM) is directly involved in the recognition of malfolded proteins for degradation (10) . IRE1 also causes cleavage of the 28S rRNA, resulting in translational repression (11) . PERK belongs to the kinase family, which specifically phosphorylates the α subunit of the eukaryotic translation initiation factor 2 [eIF2α; (12) ]. To date, four members have been identified: PERK, PKR, heme-regulated inhibitor of translation, and the mammalian homologue of yeast eIF2α kinase GCnonderepressing 2 [GCN2; (12) (13) (14) (15) ]. These kinases share similarity in the kinase domains but differ in the regulatory domains, allowing them to respond to distinct stress stimuli and phosphorylate eIF2α at the identical residue serine 51. PERK is specifically activated by ER stress (12) . Phosphorylation of eIF2α causes global inhibition of protein synthesis but at the same time, enhances translation of the transcription factor ATF4 required to transactivate specific UPR genes via the ATF4 element in their promoters (16) . (17) (18) (19) (20) . Hepatitis C virus (HCV) is a singlestranded, positive-sense RNA virus encoding a polyprotein of ~3010 amino acid residues, which mature into the core, F, envelope proteins E1 and E2, p7, and nonstructural NS2, NS3, NS4A, NS4B, NS5A, and NS5B proteins (21) . A neomycin-adapted subgenomic replicon of HCV expressing the nonstructural proteins has been shown to cause ER stress (22) . However, the subgenomic replicon does not express the core nor envelope proteins E1 and E2. Accumulation of envelope proteins in the ER has been implicated as the trigger of the UPR in several virus infections (20, 23, 24) . In the neurovirulent mouse retrovirus, it has been shown that the UPR is initiated by the retention of inefficiently folded envelope proteins in the ER (23) . Therefore, in this study, we focused our attention on the HCV envelope proteins, as they target and mature in the ER into a noncovalently bound, native, complex, and also malfolded, disulfide aggregates (25, 26) . As a result of their ER location and their tendency to form aggregates, we believe that these envelope proteins may play a role in the pathogenesis of HCV-related diseases via UPR regulation. Previously, Liberman et al. (27) have shown the involvement of the HCV E2 protein in up-regulating BiP expression. BiP is a molecular chaperone required for maintaining ER homeostasis and cell survival (1); thus, the ability to regulate BiP may confer an advantage to viral replication. However, excessive UPR leads to the induction of CCAAT/enhancer binding protein-homologous protein (CHOP), which is responsible for regulating genes required for cell growth arrest and apoptosis (4, (28) (29) (30) . To elucidate the putative role of ER stress in the pathogenesis of HCV-associated diseases, we investigated CHOP regulation as part of the UPR induced by HCV envelope protein expression. In addition, we investigated the engagement of ERAD as a result of HCV envelope protein expression.
UPR has been documented in virus infections

MATERIALS AND METHODS
Plasmids
The HCV plasmids used in this report were obtained from Tatsuo Miyamura, Yoshiharu Matsuura, Makoto Hijikata, or generated using HCV genotype 1b as templates (31) (32) (33) . The plasmids E1 and E2 encode the respective envelope proteins with their endogenous signal peptides. The plasmids gfp-E1 and gfp-E2 were constructed by subcloning E1 and E2 genes without signal peptide sequences into plasmid enhanced green fluorescent protein (GFP)-C1 (Clontech, Palo Alto, CA, USA). The sequences of the constructs were confirmed by automated sequencing using the Big Dye Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and analyzed with the program GCG. Expression of proteins of the correct sizes was confirmed using Western blotting and fluorescence microscopy. The BiP-luciferase reporter driven by -304 base pairs (bp) to +7 bp of the BiP promoter was obtained from Kazutoshi Mori (34) . The full-length CHOP-luciferase reporter, driven by 954 bp of the CHOP promoter and various deletion constructs as depicted (see Fig. 4 ), was obtained from Pierre Fafournoux (35) . The UPRE-luciferase reporter driven by six copies of the consensus XBP1 binding site sequence TGACGTGG/A was obtained from Ron Prywes (36) . The ER-targeting GFP constructed by fusing the GFP to the signal peptide of calreticulin, and the ER retention signal Lys-Asp-GluLeu (KDEL) were obtained from David Llewellyn (37).
Cell culture
HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamate. HepG2 cells were maintained in Eagle's minimal essential medium and 1× nonessential amino acids supplemented with 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamate. Wild-type (WT) mouse embryonic fibroblasts (MEFs; Perk+/+, Gcn2+/+) and MEFs deficient in PERK (Perk−/−) or GCN2 (Gcn2−/−) were obtained from David Ron and Heather Harding and have been transformed with simian virus 40 (SV40) T antigen (16, 38) . They were maintained in DMEM and 1× nonessential amino acids supplemented with 10% FCS, 55 μM β-mercaptoethanol, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamate.
Transfection
Transfection was performed according to the manufacturer's instruction using PolyFect (Qiagen, Valencia, CA, USA) for HeLa cells and MEFs and SuperFect (Qiagen) for HepG2 cells. HeLa cells were seeded in 12-well plates at a density of 1.5 × 10 5 cells per well and in six-well plates at a density of 4 × 10 5 cells per well. MEFs were seeded in 12-well plates at a density of 0.75 × 10 5 cells per well and in six-well plates at a density of 2 × 10 5 cells per well. HepG2 cells were seeded in 12-well plates at a density of 3 × 10 5 cells per well and in six-well plates at a density of 8 × 10 5 cells per well. The transfection efficiencies were in the range of 30%. To examine the effect of HCV E1 and E2 proteins on promoters, cells seeded in 12-well plates were transfected with a total of 0.5 μg DNA consisting of 0.2 μg promoter-luciferase reporter plasmid, 0.1 μg plasmid cytomegalovirus (pCMV)-β-galactosidase (β-Gal), and 0.2 μg of one of the following: 0.2 μg empty vector, 0.1 μg E1 + 0.1 μg empty vector, 0.1 μg E2 + 0.1 μg empty vector, or 0.1 μg E1 + 0.1 μg E2. The amount of DNA was always held constant with empty vector to ensure equal transfection efficiencies in these experiments. Each transfection included the pCMV-β-Gal, which is a plasmid carrying the bacterial β-Gal gene driven by the human CMV immediate-early enhancer/promoter region, to be used as an internal normalization control. Cells seeded in sixwell plates were transfected similarly, apart from scaling-up the reaction to a total of 1.5 μg DNA. The cells were harvested for reporter assays at 16 h, 48 h, or 72 h post-transfection for HeLa cells and 48 h post-transfection for MEFs and HepG2 cells. As positive and negative controls, 2 μg/ml tunicamycin or an equal amount of the solvent dimethylsulfoxide (DMSO) was added to the 48-h mock-transfected cells for 16 h before harvest. To examine the dose-dependent effect of E1 and E2 proteins on the CHOP promoter, HeLa cells seeded in 12-well plates were transfected with a total of 0.5 μg DNA consisting of 0.2 μg CHOP-luciferase reporter plasmid, 0.1 μg pCMV-β-Gal, and 0-0.1 μg E1 and/or 0-0.1 μg E2, adjusted to a total of 0.2 μg with empty vector. For Western blotting and reverse transcriptase-polymerase chain reaction (RT-PCR), HeLa cells seeded in six-well plates were transfected with a total of 1.5 μg DNA consisting of one of the following: 1.5 μg empty vector, 0.75 μg E1 + 0.75 μg empty vector, 0.75 μg E2 + 0.75 μg empty vector, or 0.75 μg E1 + 0.75 μg E2. As positive and negative controls, untransfected HeLa cells were treated with 2 μg/ml tunicamycin or an equal amount of the solvent DMSO for the indicated time intervals before harvest.
Reporter assays
After transient transfection, protein lysates harvested in lysis buffer (Roche Diagnostics, Nutley, NJ, USA) were used in luciferase and galactosidase assays. Luciferase activity was measured in 0.0165 M glycylglycine, 0.01 M MgSO 4 , 2.65 mM EGTA, 10.5 mM potassium phosphate, 1.4 mM adenosine 5′-triphosphate, 0.86 mM dithiothreitol (DTT), 0.175 mg/ml bovine serum albumin, and 0.035 mM luciferin (Roche Diagnostics) with a luminometer (Berthold Technologies, Germany). Galactosidase activity was measured in 100 mM sodium phosphate, pH 7.3, 1 mM MgCl 2 , 50 mM β-mercaptoethanol, and 0.665 mg/ml o-nitrophenyl β-Dgalactopyranoside (Sigma Chemical Co., St. Louis, MO) at 420 nm. The luciferase activities were normalized against the β-Gal activities. Statistical analyses were performed using ANOVA. A P value of less than 0.05 was considered statistically significant.
Western blotting
Protein lysates were harvested into 1× sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. The protein concentrations were measured using the Bradford reagent or the RC-DC protein assay kit from Bio-Rad (Hercules, CA, USA). Equal amounts of protein from cell lysates were resolved on 10-12% SDS-PAGE, transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA), and immunoblotted with primary antibodies followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (Amersham, Little Chalfont, UK). Immunocomplexes were detected with the Enhanced Chemiluminescence Plus system (Amersham). Antibodies specific for E1 (Lau-E1-159) and E2 (H52) were gifts of Johnson Lau (Kinex Pharmaceuticals, Buffalo, NY, USA) and Jean Dubuisson (Institut de Biologie de Lille & Institut Pasteur de Lille, France), respectively. The antibodies specific for GADD153 (CHOP) and GFP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Clontech. The following concentrations of primary and secondary antibodies were used: Lau-E1-159 1:500, anti-mouse HRP 1:100; H52 1:250, anti-mouse HRP 1:1000; GADD153 1:100, anti-mouse HRP 1:1000; GFP 1:1000, anti-mouse 1:1000. As loading controls, either the blots were stripped in 62.5 mM Tris-HCl, pH 6.7, 2% SDS, 100 mM β-mercaptoethanol at 50°C for 30 min before reprobing with 1:1000-5000 β-tubulin (Sigma Chemical Co.) followed by 1:1000-5000 anti-mouse HRP, or a separate blot was probed against β-tubulin. Recombinant proteins E2 and GFP used as standards were purchased from Austral Biologicals (San Ramon, CA, USA) and BD Biosciences (San Jose, CA, USA), respectively.
Semiquantitative RT-PCR
Total RNA was extracted from cultured cells using Trizol (Invitrogen, Carlsbad, CA, USA). RT-PCR was performed using 1 μg RNA and TITAN one-tube RT-PCR system (Roche Diagnostics) with the corresponding primer pairs: BiP 5′-caaaaagaagacgggcaaag-3′ and 5′-cagtcagatcaaatgtacccag-3′; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 5′-cctgttcgacagtcagccg-3′ and 5′-cgaccaaatccgttgactcc-3′; XBP1 5′-gctgaggaggaaactgaaaaac-3′ and 5′-tgcccaacaggatatcagac-3′; CHOP 5′-tgaggagagagtgttcaagaag-3′ and 5′-tccaggaggtgaaacatagg-3′. Primer pairs were designed with at least one of them spanning the exon-intron boundary so that only mRNA but not genomic DNA was amplified. The RT step was performed at 50°C for 30 min. PCR was carried out with 10 s denaturation at 94°C, 30 s annealing, 45 s elongation at 68°C, and the following annealing temperatures and cycles: BiP/GAPDH (55°C, 25 cycles), XBP1 (55°C, 35 cycles), CHOP (50°C, 40 cycles).
RESULTS
HCV envelope proteins activate CHOP promoter
To determine the effect of HCV envelope proteins on the CHOP promoter, we used a transient transfection system with HeLa cells and a luciferase reporter gene driven by the full-length, 954-bp CHOP promoter. Expression of E1 and E2 caused significant activation of the CHOP promoter over a time course of 16, 48, and 72 h (Fig. 1A) . As Liberman et al. (27) previously characterized the effect of HCV envelope proteins on the BiP promoter, we used this as a positive control in this study. Using a luciferase reporter gene driven by the -304 bp to +7 bp BiP promoter, we confirmed the activating effect of HCV envelope protein on the BiP promoter (Fig. 1A) . As a negative control, we used a pGL3-control vector (Promega, Madison, WI, USA), in which the luciferase reporter gene is driven by the SV40 promoter and enhancer. Expression of E1 and E2 was incapable of activating the SV40 promoter, confirming that activation of the UPR gene promoters CHOP and BiP was specific (data not shown). The specificity of the experiments was confirmed using a known, potent UPR inducer tunicamycin, which activates UPR by inhibiting protein glycosylation in the ER. Tunicamycin treatment of HeLa cells resulted in significant activation of the UPR gene promoters CHOP and BiP but not the non-UPR gene promoter SV40 (data not shown). Similar findings were observed in a hepatocyte cell line HepG2 (data not shown).
We then compared the effect of E1 and E2 on the CHOP promoter with that on the BiP promoter. In agreement with results from another group (27) , the BiP promoter was mainly activated by expression of E2 and marginally by E1 (Fig. 1A) . In contrast, the CHOP promoter was activated by E1 and E2. However, statistical analyses show that the effect of E1 and E2 was nonadditive. This may be explained by the formation of a correctly folded, native complex during coexpression of E1 and E2, thus reducing the load of malfolded proteins in relation to total protein expression in keeping with the requirement of malfolded proteins but not just overexpression of proteins in the ER for the induction of UPR.
Examination of the CHOP promoter activity over the time course revealed maximal induction at 48 h post-transfection, concomitant with the kinetics of E1 and E2 expression during cotransfection and E2 expression on its own but displaying a delayed kinetics in relation to E1 expression on its own (Fig. 1B) . During cotransfection, E1 and E2 displayed peak expression at 48 h post-transfection. Transfection with E2 alone did not change the kinetics of E2 expression. In contrast, the kinetics of E1 expression was altered in the absence of E2. Instead of 48 h posttransfection, expression of E1 now peaked at 16 h post-transfection and then gradually declined over the time course. The reduction in E1 stability in the absence of E2 is consistent with previous results, which suggest that E2 is a chaperone for E1 (39) . Although it appeared that much higher levels of E2 were expressed, this was probably a result of the difference in the sensitivity of the antibodies used in the detection. In other studies using different antibodies and expression systems, E1 and E2 proteins were found to express at similar levels in cultured cells (27, 40) .
Transient transfection systems have been widely used to generate vital information in many disease models. In this study, it could be argued that the induction of the UPR gene promoters may be a result of overloading the ER. However, the amount of E1 and E2 DNA used in each transfection was actually quite small (0.1 μg per 1.5×10 5 cells). Using Western blotting and comparison against known concentrations of recombinant E2 run on the same gel, we have estimated that the expression levels of E2 at 16 h, 48 h, and 72 h post-transfection are only 0.10 pg/cell, 0.71 pg/cell, and 0.17 pg/cell ( Fig. 2A) . Unfortunately, recombinant E1 protein was not available for similar quantification. Currently, it is not possible to make a direct comparison of the levels of envelope proteins in the cultured cells we used with those in infected cells as a result of the lack of data for infected cells in humans. Only until recently with the help of laser capture microdissection and enzyme-linked immunosorbent assay has the concentration of HCV core protein in single hepatocytes been estimated (the range is 7-56 pg/cell; ref. 41) . As E1 and E2 proteins are processed from a single polypeptide, preceded by the core protein, it is reasonable to speculate that E1 and E2 proteins are expressed at levels similar to or slightly less than that of the core protein. Thus, the estimated levels of E2 protein in our cultured cells will be in the range of the levels of expression typically observed in cells infected with HCV and can be regarded as physiologically relevant. Moreover, electron microscopy of hepatocytes from HCVinfected people has also revealed dilated ER with fluffy material within the lumen, consistent with large protein aggregates (42) . Furthermore, titration of the E1-and E2-expressing plasmids showed a dose-dependent activation (Fig. 2B) . The level of DNA as low as 0.005 μg per 1.5 × 10 5 cells still triggered an almost twofold induction of the CHOP promoter, demonstrating that even a low amount of E1 or E2 DNA was capable of activating the promoter. It should be noted that the total amount of transfected DNA was kept constant to maintain equal transfection efficiency in these experiments. To further exclude the possibility that activation of the UPR gene promoters was merely a result of expression of proteins in the ER per se, we used a GFP that had been engineered to be targeted to the ER by fusing the GFP with the signal peptide of calreticulin and the ER retention signal KDEL. Its ER localization has been verified in a previous study (37). In this study, the expression levels of GFP were measured using Western blotting and calibrated against a standard curve based on known concentrations of recombinant GFP run on the same gel (data not shown). We confirmed that expression of GFP in the ER to a similar level as that of the E2 protein was not capable of activating BiP or CHOP promoters at the three timepoints examined (data not shown).
ER targeting is essential for activation of UPR genes promoters
To illustrate activation of CHOP and BiP promoters was specific to the ER-targeting envelope proteins, we generated constructs gfp-E1 and gfp-E2 encoding GFP fusion proteins of E1 and E2 devoid of signal peptides. These GFP-envelope fusion proteins were unable to target the ER and remained in the cytoplasm because of the lack of signal peptides. The cytoplasmic localization of gfp-E1 and gfp-E2 has been confirmed by immunofluorescence (data not shown). Overexpression of cytosolic envelope proteins gfp-E1 and/or gfp-E2 in HeLa or HepG2 cells did not activate CHOP or BiP promoters (data not shown).
E1 and/or E2 induce CHOP at mRNA and protein levels
To demonstrate induction of CHOP at the mRNA level, we performed RT-PCR (Fig. 3A) . As a positive control to compare the kinetics of CHOP expression, we used a known UPR inducer tunicamycin. In contrast to BiP, which was expressed constitutively at a moderate basal level in noninduced cells (i.e., DMSO-treated or 0 h tunicamycin-treated), or cells transfected with an empty vector, the basal transcriptional level of CHOP was low. Tunicamycin treatment induced transient transcription of CHOP that peaked at 6 h. In contrast, CHOP mRNA, induced by HCV envelope proteins E1 and/or E2, was more sustained and was observed at 16 h and 48 h posttransfection. As a result of the extremely low level of basal CHOP transcription, it was difficult to quantify the fold increase accurately. As a result, the estimated two-to threefold increases detected at 16 h and 48 h post-transfection were probably an underestimation of the magnitude of responses. CHOP induction was also detected at the protein level in E1-and E2-expressing cells using Western blotting (Fig. 3B) . No basal level of CHOP protein was detected in vectortransfected cells.
E1 and/or E2 activate ERSE and the ATF4 element in the CHOP promoter
Two responsive elements have been identified in the CHOP promoter: the ERSE and the ATF4 element. Differential use of these promoter elements under various stress conditions has been documented (35, 43) . To assess the relative contribution of these responsive elements in CHOP regulation in the context of HCV protein expression, we used deletion promoter constructs encompassing the ERSE and/or the ATF4 element (Fig. 4) . Deletion of the ERSE and ATF4 element resulted in complete abolition of the CHOP promoter activities. The ERSE or the ATF4 element alone was sufficient for eliciting full promoter activity in response to HCV envelope protein expression. Although higher promoter activities were observed in E1 and E2 cotransfected cells, the effect is not significant enough to be additive. Similar results were obtained using the UPR inducer tunicamycin, suggesting that redundancy in ERSE and ATF4 responsiveness may be a general property of the UPR.
PERK is essential for CHOP induction by E1 and/or E2
Using mouse embryonic stem cells deficient in PERK, it has been shown that PERK is absolutely required for CHOP induction in response to common ER stress inducers tunicamycin, thapsigargin, and DTT (16) . To evaluate the role of PERK in HCV envelope protein-induced UPR, we expressed the E1 and E2 proteins in MEFs deficient in the ER stress kinase PERK. CHOP promoter activity was induced in WT Perk+/+ MEFs but was completely abolished in Perk−/− MEFs, suggesting that PERK is necessary and sufficient for CHOP activation by E1 and/or E2 (Fig. 5A) . To confirm that the mutant cells were able to mount an UPR, we tested activation of the BiP promoter in E1-and E2-expressing cells. BiP promoter was activated in WT Perk+/+ MEFs and mutant Perk−/− MEFs. The attenuated response observed in Perk−/− MEFs was in concordance with the presence of other upstream signaling pathways for BiP activation (16) . Another eIF2α kinase, the mammalian GCN2, induces CHOP gene expression upon amino acid starvation (16) . CHOP induction in response to E1 and/or E2 transfection was unimpaired in Gcn2−/− cells compared with that of the WT Gcn2+/+ cells, confirming that CHOP induction by E1 and/or E2 is specific to the ER stress kinase PERK. To test whether the inability of the envelope proteins to activate CHOP promoter in Perk−/− MEFs was a result of a failure of these proteins to express in the PERK-deficient cells, Western blotting was used (Fig.  5B) . Envelope protein expression was detected in all the cell lines examined.
E1 and/or E2 induce XBP1 splicing
In mammalian cells, UPR is regulated not only by the ER stress kinase PERK but also by the transcription factors ATF6 and XBP1 (1) . To examine the role of XBP1 in the induction of UPR by HCV envelope protein expression, we used a unique UPR event of XBP1 splicing, which involves removal of a 26-bp of XBP1 mRNA by a spliceosome-independent, unconventional splicing mechanism initiated by the endoRNase activity of IRE1 (9) . We designed primers flanking the excised portion of XBP1 mRNA to reveal the unspliced and spliced variants in RT-PCR. This technique has been widely used to demonstrate XBP1 activation. Using tunicamycin as a positive UPR control, we revealed that the unspliced XBP1 was expressed constitutively in noninduced cells (i.e., DMSO-treated or 0 h tunicamycin-treated; Fig. 6A ). Tunicamycin treatment caused processing of the unspliced variant into the spliced variant, which peaked at 8 h and then slowly but gradually returned to near control levels at 16 h post-treatment, accompanied by a transient increase in the transcript level. This is in agreement with XBP1 splicing being an early and transient event of the UPR (44) . Similarly, expression of HCV envelope proteins also resulted in transient XBP1 splicing, detectable at 16 h but not 48 h post-transfection (Fig. 6) . XBP1 splicing is a signature event indicative of UPR induction. No background splicing occurred in noninduced cells (i.e., DMSO-treated or 0 h tunicamycin-treated) nor cells transfected with an empty vector. Therefore, despite the low levels of XBP1 splicing in E1-and E2-expressing cells, XBP1 activation was evident, and its effect on downstream signaling could be significant.
HCV envelope proteins transactivate UPRE
To further illustrate the significance of XBP1 splicing, we examined the effect of E1 and E2 expression on a downstream target of XBP1. The UPRE in the promoters of ERAD genes is a unique XBP1 binding site (10) . Using a luciferase reporter gene driven by six copies of the UPRE, high levels of the UPRE promoter activity were detected in E1-and E2-expressing HeLa and HepG2 cells (Fig. 7) . Despite the low levels of XBP1 splicing in these cells, the magnitude of UPRE activation was similar to that induced by the potent UPR inducer tunicamycin, confirming the significance of XBP1 splicing in downstream signaling in E1-and E2-expressing cells.
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DISCUSSION
It has now become evident that malfolding of proteins in the ER induces UPR and is the cause of many human diseases. Despite the documentation of UPR induction in several virus infections, the role of viral envelope proteins in the pathogenesis of diseases is only just emerging. A recent publication demonstrated that retention of an inefficiently folded envelope protein in the ER was responsible for the pathogenesis of murine spongiform neurodegenerative disease caused by a retrovirus (23) . In the case of a chronic infection such as HCV, the retention of the envelope proteins in the ER and their ability to form aggregates may predispose cells to constant ER stress and may be responsible for the pathogenesis of HCV-related diseases. A previous study showed that the HCV E2 protein activated the BiP pathway (27) . However, the diversity of cellular molecules and intracellular signaling pathways involved in the determination of cell fate during ER stress means that a thorough understanding of HCV disease pathogenesis can only be gained by dissecting the molecular components and pathways that contribute to ER stress, cell death, and cell survival in HCV-associated diseases. This is especially true in the case of HCV, as the infection can be involved in a spectrum of diseases involving cell death and cell growth. This includes hepatitis, fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma. In this study, we extended the findings of Liberman et al. (27) to the CHOP and IRE1-XBP1 pathways, which should allow a better understanding of pathogenesis in HCV-related diseases. BiP, CHOP, IRE1, and XBP1 play different and sometimes opposing roles in the UPR in the regulation of cell death and cell survival. It is interesting that cell fate and therefore outcome of diseases could be determined by the interplay of these molecules. Activation of CHOP and IRE1 is potentially cytopathic. CHOP sensitizes cells to apoptosis by down-regulation of Bcl-2 expression, depletion of cellular glutathione, and exaggerated production of reactive oxygen species (45). Although we did not directly show IRE1 activation in this study, XBP1 splicing is indicative of IRE1 activation, as XBP1 is uniquely spliced by the endoRNase activity of IRE1 (9) . IRE1 signaling induces apoptosis via the IRE1, tumor necrosis factor receptor-associated factor 2 (TRAF2), apoptosis signal-regulating kinase 1, c-Jun amino-terminal kinase, and IRE1-TRAF2-caspase 12 pathways (46) (47) (48) . Therefore, the ability to induce CHOP and IRE1 may imply a cytopathic role for HCV envelope proteins. Indeed, E1 and E2 proteins have been shown to induce apoptosis in cultured cells (49, 50) .
During the course of HCV infection, chronic hepatitis may progress to hepatocellular carcinoma (HCC). It can be envisaged that the immediate cytopathic effect of ER stress as a result of CHOP and IRE1 activation may be the underlying cause of hepatitis. In an attempt to rescue cells from ER stress, XBP1 is activated to trigger the two cellular adaptive responses, UPR and ERAD. Thus, XBP1 activation may contribute indirectly to HCC via up-regulation of its target gene BiP. A number of reports have implicated BiP in carcinogenesis (51, 52) . Conversely, XBP1 may contribute directly to HCC. XBP1 is also essential for hepatocyte growth; thus, chronic activation of XBP1 may have conferred a proliferative advantage to the stressed cells, which will ultimately lead to tumor formation (53) . Indeed, XBP1 has been found to express to a high level in human HCC (54) . In another study, human HCC was not associated with the total level of XBP1 mRNA but with the appearance of spliced XBP1 transcript (52) . Among those HCC tissues examined, the degree of XBP1 splicing was slight, in support of our findings that even with a small degree of splicing, XBP1 was still able to activate downstream targets to exert its biological effect.
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Within the CHOP promoter, there are two responsive elements, the ERSE and the ATF4 (43) . It has been suggested that during ER stress, ATF6 and XBP1 are responsible for transactivation of the ERSE, whereas a pathway dependent on PERK-mediated eIF2α phosphorylation and ATF4 translation is responsible for transactivation of the ATF4 element (43) . We showed that both responsive elements were activated by HCV envelope protein expression and that PERK is necessary and sufficient for the induction of CHOP, in concordance with results obtained from Perk−/− mouse embryonic stem cells showing that CHOP induction by common ER stress inducers is highly Perk-dependent (16) . This implies the presence of other signaling pathways downstream of PERK, which are independent of ATF4 in CHOP induction, and highlights the potential of pathway "crosstalk" between the PERK pathway and other stress-induced pathways.
BiP has been attributed to a pivotal role as a negative regulator of the UPR by binding to and repressing the activities of the three proximal UPR sensors: PERK, IRE1, and ATF6 (6, 7). Accumulation of malfolded proteins dissociates BiP from binding to the UPR sensors, allowing their activation by dimerization or migration into the Golgi (6, 7). The ability of E2 to activate the UPR can be attributed to their property to bind BiP (27, 55) . However, the inability or inefficiency of E1 to bind BiP leads us to speculate a different transduction mechanism in the induction of UPR by E1 and perhaps E2 (27, 55, 56) . One plausible mechanism is that E1/E2 impairs the degradative function of the proteasome. Recent evidence suggests a regulatory loop between ERAD and UPR (2). Efficient ERAD requires an intact UPR, whereas loss of ERAD results in constitutive UPR induction (57) . The role of ERAD impairment in pathogenesis has now become appreciated. Impairing the proteasome degradative function has been proposed as a mechanism of UPR induction in neurodegenerative diseases caused by polyglutamine aggregation (46) . During HCV infection, there is evidence of retrograde transport of E1 from the ER to the cytoplasm for proteasome degradation based on the detection of a deglycosylateddeamidated T-epitope from an HCV-infected chimpanzee (58) . In our time-course study, we detected a more transient expression of E1 in the absence of E2, suggesting a more rapid degradation of E1, which may ultimately overwhelm the ERAD leading to UPR induction. We also obtained evidence of ERAD engagement in cells transfected with E1 and/or E2 by the demonstration of XBP1 splicing and UPRE induction in these cells. The IRE-XBP1 pathway has been shown to be responsible for UPRE-mediated transcriptional induction of the EDEM protein, which is directly involved in the recognition of malfolded proteins for degradation (10) . Therefore, the detection of XBP1 splicing in E1-and/or E2-transfected cells leads us to speculate on a role in the induction of ERAD in response to HCV envelope protein expression. 16, 48 , and 72 h. Protein lysates were used in immunoblots with antibodies specific for E2 (H52). The expression levels of E2 were compared with known concentrations of recombinant E2 run on the same gel. After adjusting to the transfection efficiency and the dilution factors, the estimated E2 levels were 0.10 pg/cell, 0.71 pg/cell, and 0.17 pg/cell in 16 h-, 48 h-, and 72 h-transfected cells. B) HeLa cells seeded in 12-well plates were transfected with a total of 0.5 µg DNA consisting of 0.2 µg CHOP-luciferase reporter plasmid, 0.1 µg internal normalization control pCMV-β-Gal, and 0-0.1 µg E1 and/or 0-0.1 µg E2 adjusted to a total of 0.2 µg with empty vector. Cell lysates were harvested at 48 h post-transfection and assayed for luciferase and β-Gal activities. The promoter levels, as measured by the luciferase activities, were normalized against β-Gal activities and expressed as fold induction relative to the vector control, which was set as 1. All values represent mean ± SEM of three independent experiments performed in triplicate. were transfected with 0.6 µg respective CHOP deletion promoter-luciferase (LUC) reporter plasmid, 0.3 µg internal normalization control pCMV-β-Gal, and 0.6 µg of one of the following: 0.6 µg empty vector (vector), 0.3 µg E1 + 0.3 µg empty vector (E1), 0.3 µg E2 + 0.3 µg empty vector (E2), or 0.3 µg E1 + 0.3 µg E2 (E1+E2). Transfection efficiencies were in the range of 30%. As positive and negative controls, 2 µg/ml tunicamycin (Tm) or an equal amount of DMSO was added to the mock-transfected cells for 16 h before harvest. The cells were harvested at 48 h post-transfection and assayed for luciferase and β-Gal activities. The promoter levels, as measured by the luciferase activities, were normalized against β-Gal activities and expressed as fold induction relative to the DMSO or vector controls, which were set as 1. All values represent mean ± SEM of three to four independent experiments performed in triplicate. *, Significance of the difference, followed by the P values. . Transfection efficiencies were in the range of 30%. The cells were harvested at 48 h posttransfection and assayed for luciferase and β-Gal activities. The promoter levels as measured by the luciferase activities were normalized against β-Gal activities and expressed as fold induction relative to the vector control, which was set as 1. All values represent mean ± SEM of three to four independent experiments performed in triplicate. *, Significance of the difference, followed by the P values. B) MEFs seeded in six-well plates were transfected with similar protocol as that used for reporter assays, apart from scaling up the reaction to a total of 1.5 μg. Protein lysates harvested at 48 h post-transfection were used in immunoblots with antibody specific for E2 (H52). The blots were stripped and reprobed with β-tubulin. The E2 proteins migrated as multiple species. The bands seen in the vector and E1 lanes were nonspecific. . HCV E1 and/or E2 transactivate UPRE. HeLa and HepG2 cells seeded in six-well plates were transfected with 0.6 µg UPRE-luciferase reporter plasmid, 0.3 µg internal normalization control pCMV-β-Gal, and 0.6 µg of one of the following: 0.6 µg empty vector (vector), 0.3 µg E1 + 0.3 µg empty vector (E1), 0.3 µg E2 + 0.3 µg empty vector (E2), or 0.3 µg E1 + 0.3 µg E2 (E1+E2). Transfection efficiencies were in the range of 30%. As positive and negative controls, 2 µg/ml tunicamycin (Tm) or an equal amount of DMSO was added to the 48-h mock-transfected HeLa cells for 16 h before harvest. HeLa cells were harvested at 16 h, 48 h, and 72 h post-transfection. HepG2 cells were harvested at 48 h posttransfection. Cell lysates were assayed for luciferase and β-Gal activities. The promoter levels, as measured by the luciferase activities, were normalized against β-Gal activities and expressed as fold induction relative to the DMSO or vector controls, which were set as 1. All values represent mean ± SEM of three to four independent experiments performed in triplicate. *, Significance of the difference, followed by the P values.
